Skip to main content
. 2016 Aug 22;7(38):62377–62385. doi: 10.18632/oncotarget.11481

Figure 3. High CD81 expression on blast cells predicts poor outcome in AML.

Figure 3

Survival curves of A. OS, B. EFS, C. RFS stratified by CD81 expression measured in diagnostic bone marrow of AML patients. Shown is the survival of patients with AML either CD81 in green (less than 20%), CD81+ in black (20 to 50%), or CD81++ in red (greater than 50%). Numbers at risk at each year of follow-up are given. P-values based on logrank test.